Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Frost & Sullivan Applauds Galena Biopharma Inc For Its Breast Cancer Vaccine, NeuVax


Tuesday, 12 Mar 2013 07:45am EDT 

Galena Biopharma Inc announced that based on its recent analysis of the breast cancer vaccines market, Frost & Sullivan recognizes Galena Biopharma, Inc. with the 2013 Global Frost & Sullivan Award for New Product Innovation. The Company's product, NeuVax, has the potential to address a huge unmet medical need for a breast cancer vaccine and provide cost-savings to both patients and governments. NeuVax (nelipepimut-S or E75), a nonapeptide, derived from the human epidermal growth factor receptor 2 (HER2) oncogene, is co-administered with the immunoadjuvant granulocyte macrophage colony-stimulating factor (GM-CSF) in an intradermal injection. It is the first breast cancer vaccine to reach Phase III clinical trials and could very well emerge as an off-the-shelf cancer immunotherapy treatment to prevent recurrence. In Phase II studies, NeuVax was shown to prevent or delay breast cancer recurrence in women with early-stage, high-risk (node positive), HER2 low-to-intermediate (immunohistochemical (IHC) 1+/2+ or fluorescent in situ hybridization (FISH) <2.2) disease. NeuVax immunotherapy uses the patient's own immune system to target tumor cells in a highly-specific, less toxic and more-convenient way than conventional cancer therapies. Multiple clinical trials have proven that NeuVax is safe and effective in stimulating cytotoxic (CD8+) T-cells in a highly specific manner to target HER2 expressing cells. 

Company Quote

1.62
-0.01 -0.61%
18 Dec 2014